-+ 0.00%
-+ 0.00%
-+ 0.00%

Evolus expects sustained adjusted EBITDA profitability beginning in 2026

PUBT·11/04/2026 22:42:41
Listen to the news
Evolus expects sustained adjusted EBITDA profitability beginning in 2026
  • Evolus expects sustainable adjusted EBITDA profitability beginning in 2026, with funding in place to reach that goal.
  • Revenue reached $297.2 million in 2025, up from $266.3 million in 2024, marking six consecutive years of double-digit growth.
  • U.S. approval of Evolysse Sculpt is expected by year-end 2026; Evolysse Lips is targeted for year-end 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evolus Inc. published the original content used to generate this news brief on November 04, 2026, and is solely responsible for the information contained therein.